~~<i id='A504123DF5'><strike id='A504123DF5'><tt id='A504123DF5'><pre id='A504123DF5'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

focus

author：hotspot 2025-08-27 19:00:06 - browse：7

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： IVG is promising — but it won’t replace IVF quite yet

focus

leisure time

Wikipedia

explore

hotspot

focus

JustinSullivan/GettyImagesVaccinationratesagainstfluandCovid-19havedeclinedsinceearlierinthepandemic

WSS

6 solutions to address cancer drug shortages and others

New oral drug delivery patch is modeled after octopus tentacles

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

What is STAT's opinion section for?

Experts study whether long Covid risk adds up with each reinfection

First transplant of an entire human eye performed

entertainment

focus

focus

Walensky prepares to leave CDC — and Congress — behind

6 solutions to address cancer drug shortages and others

Duchenne breakthrough therapy leaves behind pioneering families

Congress extends some pandemic preparedness programs

Bright Health sells Medicare Advantage business to Molina

6 solutions to address cancer drug shortages and others

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

2023 Nobel Prize in Medicine goes to Karikó and Weissman

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Study suggests Covid rebound is far more common with Paxlovid than without

leisure time

Experimental asthma app from Apple and Anthem shows promise

Congress extends some pandemic preparedness programs

Nobel honors Karikó and Weissman's enduring partnership

NIH chief: government has fallen behind pharma on clinical trials

IVG is promising — but it won’t replace IVF quite yet

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Wikipedia

explore

hotspot

focus